Protein Tyrosine Kinases (PTK) in Multiple Myeloma

Inclusion Criteria:

• Older than 18 years of age.
• Confirmed diagnosis of active progressive multiple myeloma
• History of > 2 prior cytotoxic treatment regimens. Bone marrow transplantation will be considered as one regimen.
• Current measurable disease based on serum and/or urine M protein and/or measurable plasmacytoma.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
• Absolute neutrophil count (ANC) > 1,500 mm3
• Platelets > 100,000 mm3
• Serum creatinine < 1.5 upper limit of normal (ULN)
• Serum bilirubin < 1.5 ULN
• AST/AGOT and ALT/SGPT < 3.0 ULN
• Life expectancy > 12 weeks

Exclusion Criteria:

• Chemotherapy < 3 weeks prior to registration.
• Biologic or immunotherapy < 2 weeks prior to registration
• Full field radiotherapy < 4 weeks or limited field radiotherapy < 2 weeks prior to registration.
• History or presence of central nervous system (CNS) disease
• History of leukemia
• History of another primary malignancy with the exception of inactive basal or squamous cell carcinoma of the skin
• Major surgery < 4 weeks prior to registration
• Prior therapy with anti-vascular endothelial growth factor (VEGF) agents excluding thalidomide, Revimid, velcade and arsenic trioxide
• Interstitial pneumonia or extensive and symptomatic interstitial fibrosis of the lung
• Pleural effusion or ascites that cause respiratory compromise
• Female patients that are pregnant or breast feeding
• Uncontrolled high blood pressure, history of labile hypertension or history of poor compliance with an antihypertensive regimen
• Unstable angina pectoris
• Symptomatic congestive heart failure
• Myocardial infarction < 6 months prior to registration
• Serious uncontrolled cardiac arrhythmia
• Uncontrolled diabetes
• Active or uncontrolled infection
• Acute or chronic liver disease
• Impairment of gastrointestinal (GI) function or GI disease
• Confirmed HIV infection